Archive by Author

Tagline Competition and Innovator’s Pitch Challenge Applications open for RESI South

26 Jan

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiStand Out at RESI South

Redefining Early-Stage Investments (RESI) South conference is set to take place in person on March 25 at the Whitley Atlanta Buckhead in Atlanta, followed by two days of virtual partnering. RESI South in Atlanta is particularly significant as it will showcase the burgeoning life science innovation ecosystem in the Southeastern United States. The Southeast LifeSci Investor Coalition, representing seven southern states (AL, FL, GA, NC, SC, TN, and VA), has united to spotlight the region’s wealth of early-stage drugs, devices, diagnostics, and digital health technologies. Thousands of startups are invigorating this innovation region. LSN estimates that hundreds of startups with technology transfer licenses are ready to explore the partnering opportunities that RESI South will bring.

Applications for the Innovator’s Pitch Challenge are now open for RESI South. The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage life science and healthcare companies to apply to gain additional exposure to conference attendees and pitch directly to a panel of judges, featuring active investors and industry experts. Each finalist company also prepares a posterboard to be showcased in the exhibit hall and competes for “RESI Cash” which attendees use to “invest” in their favorite presenters for the final prizes.

LSN is running a Tagline Competition, and the winners will receive tickets to RESI South. The tagline serves as the foundation of your company’s identity, encapsulating it in a single line. Crafting an effective tagline demands meticulous attention to detail. Entrepreneurs are challenged to articulate their company’s essence in 5-8 words, ideally encompassing the technology modality, indication procedure, and unique qualities. A compelling tagline is paramount for making a positive first impression, enabling investors to quickly gauge alignment with their interests. How can you distill your identity into a single line and create a lasting impression for potential investors? Submit your tagline by February 7. The announcement of winners and promotion of their taglines will feature in our Next Phase newsletter, reaching LSN’s expansive readership of 45,000+.

Submit_Your_TaglineSubmit Your Tagline by February 7

RESI-South-2024-11oo

Share Your Standout Tagline for a Shot at Winning RESI South Tickets – Don’t Miss Out! 

25 Jan

By Cameron Hurlburt, Director of Business Development, LSN

Life Science Nation (LSN) is gearing up for the Redefining Early-Stage Investments (RESI) South debut conference set to take place in-person on March 25 at the Whitley Atlanta Buckhead in Atlanta, followed by two days of virtual partnering. LSN is actively involved in supporting early-stage startups through educational boot camps, free online webinars, and consulting. The tagline holds a pivotal role in our communication strategy with clients as they prepare to perfect their pitch.

Explore the Power of Your Message: Your tagline serves as the foundation of your company’s identity, encapsulating it in a single line. Crafting an effective tagline demands meticulous attention to detail. Entrepreneurs are challenged to articulate their company’s essence in 5-8 words, ideally encompassing the technology modality, indication procedure, and unique qualities. A compelling tagline is paramount for making a positive first impression, enabling investors to quickly gauge alignment with their interests. How can you distill your identity into a single line and create a lasting impression for potential investors?

Share Your Tagline! Life Science Nation will assess and recognize the top tagline submissions. Winners will receive a complimentary RESI South registration, covering a standard 3-day registration, inclusive of in-person partnering on March 25th, and two days of virtual partnering on March 26-27. In honor of  RESI South, a winner will be chosen from each of the seven states represented by RESI co-organizer, the SE LifeSci Investor Coalition, and an additional three winners chosen nationally. 

The announcement of winners and promotion of their taglines will feature in our Next Phase newsletter, reaching LSN’s expansive readership of 45,000+. Don’t miss out on this opportunity—submit your tagline to us ASAP!

Submit_Your_TaglineSubmit Your Tagline by February 28

RESI-South-2024_02062024.

Register-now-button-new

RESI South 2024 Innovator’s Pitch Challenge (IPC) application is now open!

25 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage life science and healthcare companies to apply to gain additional exposure to conference attendees and pitch directly to a panel of judges, featuring active investors and industry experts. Each finalist company also prepares a posterboard to be showcased in the exhibit hall and competes for “RESI Cash” which attendees use to “invest” in their favorite presenters for the final prizes.

Learn more about the IPC and hear from 2023 winners. The following interviews were with companies and founders who have found value in the process and connections associated with their pitch experience with RESI:

RESI-South-2024-11oo

Introducing Investor Panels for RESI South, March 2024 

25 Jan

By Max Braht, Investor Research Analyst, LSN

Max-Braht-Headshot

Life Science Nation is thrilled to be bringing our Redefining Early Stage Investments (RESI) conference to Atlanta, Georgia with RESI South, March 2024. The conference, which has served as a catalyst for connecting early-stage life science companies with investors and licensing partners for over a decade, will take place in person on March 25 at The Whitley Atlanta Buckhead Hotel and will be followed by two days of virtual partnering on March 26– 27. In addition to partnering, the Innovator’s Pitch Challenge, and educational workshops, RESI will feature seven investor panels, including a return of popular panel topics as well as new content.

Each panel will feature a unique group of experienced investors and industry experts discussing some of the most relevant and impactful topics within the life sciences investment space. A full list of panel topics can be found below. Be sure to register before Friday, February 2 for Super Early Bird ticket pricing to save $500.

RESI South 2024 Investor Panels
All sessions are scheduled for Eastern Time (ET)
9 AM Corporate VC
Firms Investing Beyond Financial Return
10 AM New, Now, and Next in Longevity Investment
Opportunities and Priorities in Age-Related Disease Therapies
11 AM AI in Healthcare
Integrating Science and Technology to Create Disruptive Innovations
12 PM Lunch
1 PM Chronic Disease Therapeutics
Innovative Therapies for Long-Term, Self-Empowered Health
2 PM Seed Funds
Investing in Innovation in the Earliest Stages
3 PM CNS Diseases
Advancing Novel Drugs & Therapies in CNS Disorders
4 PM Digital Health
Novel Approaches to Improve Quality of Care
5 PM Cocktail Reception and IPC Winner Announcement

Panel recruitment remains ongoing, as we seek out speakers and their unique experiences throughout early-stage investing. If you are an accredited investor and are interested in joining any of these panels, please contact the LSN research team at research@lifesciencenation.com.

RESI-South-2024-11oo

Hot Investor Mandate: Healthcare VC Invest Up to $15M in All Areas of Life Sciences and Healthcare, Preferring to See Early Clinical Data  

25 Jan

A healthcare and life sciences focused venture capital firm based in US and China has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD. The firm prefers to lead, especially for US and China based deals but is open to co-investing. The firm primarily considers companies based in the US and China but is open to opportunities globally. 
 
The firm looks for new opportunities in therapeutics, medical devices, medical services, the diagnostics (IVD) space and healthcare IT. The firm is opportunistic in terms of subsectors and indications. For therapeutics, the firm would like to see some clinical data or safety data. 
 
The firm does not have specific requirements for the management team. Management teams with successful track records would be preferable. The firm will likely seek board seats on a case-by-case basis. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Western Europe-Based Firm Invests Globally in Life Sciences & Healthcare Companies With Inaugural Fund 

25 Jan

A Venture Capital firm based in Western Europe invests exclusively in the life science space and is currently investing out of their first fund. The firm looks to invest in early-stage life science companies crossing all sectors and is opportunistic in terms of subsector and indication. The firm focuses on Pre-Seed, Seed, Series A and Series B investments and investments are in the form of equity. The firm makes investments ranging from $50K to $3M per round. The firm will consider opportunities globally. 
 
In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, digital health, medical device and femtech sectors. The firm is open to pre-clinical therapeutic companies and all three classes of medical devices. The firm has a broad investment interest and is opportunistic in terms of sub-sectors and indications. 
 
The firm looks for all types of management teams, however a proven track record is a plus. The firm is open to both leading and co-investing. If the firm leads, they seek board seat representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: VC Firm with US & China Operations Invests in Early and Growth-Stage Novel Therapeutics Companies Globally

25 Jan

The firm is a life science venture capital firm with strong China expertise and global capabilities. Founded in 2017, the firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in Boston, Shanghai, as well as Palo Alto. 
 
The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage. 
 
The firm has no specific requirement for the company & management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com